|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LIN54 |
Gene summary for LIN54 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LIN54 | Gene ID | 132660 |
| Gene name | lin-54 DREAM MuvB core complex component | |
| Gene Alias | CXCDC1 | |
| Cytomap | 4q21.22 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6MZP7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 132660 | LIN54 | LZE2T | Human | Esophagus | ESCC | 7.49e-04 | 3.40e-01 | 0.082 |
| 132660 | LIN54 | LZE4T | Human | Esophagus | ESCC | 6.45e-05 | 1.08e-01 | 0.0811 |
| 132660 | LIN54 | LZE24T | Human | Esophagus | ESCC | 1.57e-06 | 1.12e-01 | 0.0596 |
| 132660 | LIN54 | P2T-E | Human | Esophagus | ESCC | 1.04e-17 | 3.19e-01 | 0.1177 |
| 132660 | LIN54 | P4T-E | Human | Esophagus | ESCC | 4.92e-03 | 1.13e-01 | 0.1323 |
| 132660 | LIN54 | P5T-E | Human | Esophagus | ESCC | 7.34e-03 | 8.39e-02 | 0.1327 |
| 132660 | LIN54 | P8T-E | Human | Esophagus | ESCC | 2.10e-03 | 1.17e-01 | 0.0889 |
| 132660 | LIN54 | P9T-E | Human | Esophagus | ESCC | 4.95e-04 | 9.88e-02 | 0.1131 |
| 132660 | LIN54 | P10T-E | Human | Esophagus | ESCC | 2.36e-03 | 7.48e-02 | 0.116 |
| 132660 | LIN54 | P11T-E | Human | Esophagus | ESCC | 4.81e-02 | 1.70e-01 | 0.1426 |
| 132660 | LIN54 | P12T-E | Human | Esophagus | ESCC | 6.79e-08 | 1.61e-01 | 0.1122 |
| 132660 | LIN54 | P15T-E | Human | Esophagus | ESCC | 7.40e-12 | 1.97e-01 | 0.1149 |
| 132660 | LIN54 | P16T-E | Human | Esophagus | ESCC | 3.86e-11 | 1.70e-01 | 0.1153 |
| 132660 | LIN54 | P17T-E | Human | Esophagus | ESCC | 5.49e-03 | 1.18e-01 | 0.1278 |
| 132660 | LIN54 | P21T-E | Human | Esophagus | ESCC | 2.84e-05 | 7.78e-02 | 0.1617 |
| 132660 | LIN54 | P22T-E | Human | Esophagus | ESCC | 6.16e-04 | 4.45e-02 | 0.1236 |
| 132660 | LIN54 | P23T-E | Human | Esophagus | ESCC | 4.81e-10 | 2.19e-01 | 0.108 |
| 132660 | LIN54 | P24T-E | Human | Esophagus | ESCC | 7.94e-05 | 9.30e-02 | 0.1287 |
| 132660 | LIN54 | P26T-E | Human | Esophagus | ESCC | 8.89e-10 | 1.84e-01 | 0.1276 |
| 132660 | LIN54 | P27T-E | Human | Esophagus | ESCC | 6.44e-04 | 1.18e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LIN54 | SNV | Missense_Mutation | c.2075N>G | p.Glu692Gly | p.E692G | Q6MZP7 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LIN54 | SNV | Missense_Mutation | c.167N>G | p.Ser56Cys | p.S56C | Q6MZP7 | protein_coding | tolerated_low_confidence(0.07) | benign(0) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| LIN54 | SNV | Missense_Mutation | rs759113603 | c.1030A>G | p.Thr344Ala | p.T344A | Q6MZP7 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LIN54 | SNV | Missense_Mutation | c.1766G>C | p.Gly589Ala | p.G589A | Q6MZP7 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LIN54 | SNV | Missense_Mutation | c.315G>C | p.Gln105His | p.Q105H | Q6MZP7 | protein_coding | tolerated_low_confidence(0.12) | possibly_damaging(0.496) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| LIN54 | SNV | Missense_Mutation | novel | c.577N>A | p.Glu193Lys | p.E193K | Q6MZP7 | protein_coding | tolerated(0.05) | benign(0.038) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| LIN54 | SNV | Missense_Mutation | novel | c.332N>T | p.Ser111Leu | p.S111L | Q6MZP7 | protein_coding | deleterious_low_confidence(0.01) | benign(0.334) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| LIN54 | SNV | Missense_Mutation | c.1388N>T | p.Pro463Leu | p.P463L | Q6MZP7 | protein_coding | tolerated(0.08) | possibly_damaging(0.738) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LIN54 | SNV | Missense_Mutation | c.1513N>T | p.Ala505Ser | p.A505S | Q6MZP7 | protein_coding | tolerated(0.24) | benign(0.015) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| LIN54 | SNV | Missense_Mutation | c.2158N>T | p.Arg720Trp | p.R720W | Q6MZP7 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |